Skip to main content
. 2014 Jul 7;20(25):8187–8194. doi: 10.3748/wjg.v20.i25.8187

Table 2.

Acid-suppressive therapy and other medications in peritonitis group and no peritonitis group n (%)

Peritonitis group No peritonitis group P value
(n = 61) (n = 59)
Use of PPIs 6 (9.8) 10 (16.9) 0.252
≤ 7 d 5 (8.2) 4 (6.8) 0.691
8-30 d 0 (0.0) 1 (1.7)
> 30 d-1 yr 1 (1.6) 5 (8.5)
No use 55 (90.2) 49 (83.1)
Use of H2Bs 15 (24.6) 4 (6.8) 0.011
≤ 7 d 7 (11.5) 3 (5.1) 0.041
8-30 d 1 (1.6) 0 (0.0)
> 30 d-1 yr 7 (11.5) 1 (1.7)
No use 46 (75.4) 55 (93.2)
Use of other antacids 4 (6.6) 3 (5.1) 1.000
≤ 7 d 3 (1.9) 1 (1.7) 0.472
8-30 d 1 (0.0) 1 (1.7)
> 30 d-1 yr 0 (1.9) 1 (1.7)
No use 57 (96.2) 56 (94.9)
Use of prokinetics 20 (32.8) 18 (30.5) 0.789
≤ 7 d 11 (18.0) 10 (16.9) 0.712
8-30 d 2 (3.3) 0 (0.0)
> 30 d-1 yr 7 (11.5) 8 (13.6)
No use 41 (67.2) 41 (69.5)
Use of immunosuppressants 4 (6.6) 3 (5.1) 1.000
≤ 7 d 2 (3.3) 1 (1.7) 0.610
8-30 d 0 (0.0) 0 (0.7)
> 30 d-1 yr 2 (3.3) 2 (3.4)
No use 57 (93.4) 56 (94.9)

PPIs: Proton pump inhibitors; H2B: H2-blockers.